Welcome to our dedicated page for Disc Medicine SEC filings (Ticker: IRON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Disc Medicine filings document the regulatory and financial record of a clinical-stage biopharmaceutical company developing hematologic disease therapies. Its Form 8-K disclosures cover quarterly and annual financial results, corporate updates, clinical-program materials for bitopertin, DISC-0974 and DISC-3405, and FDA communications related to the bitopertin New Drug Application for erythropoietic protoporphyria.
The filing record also includes proxy materials covering board matters, executive compensation and shareholder voting items. Material-event reports describe Regulation FD presentations, operating runway disclosures, restructuring actions following regulatory developments, and risk-related statements around clinical trials, regulatory pathways, research spending and capital resources.
Disc Medicine, Inc. director Georges Gemayel received a grant of stock options covering 6,212 shares of common stock. The options have an exercise price of $70.79 per share and expire on June 17, 2036, bringing his reported derivative holdings to 6,212 options.
The options vest on the earlier of the company’s 2027 annual stockholder meeting or the one-year anniversary of the grant date, as long as he continues to serve as a director on the vesting date.
Disc Medicine director Mark Chin received a new stock option grant. On the reported date, he was awarded options covering 6,212 shares of Disc Medicine common stock at an exercise price of $70.79 per share, expiring on June 17, 2036.
The options were granted as compensation and carry no upfront purchase cost, with a grant price of $0.00. According to the terms, the underlying shares vest on the earlier of the company’s 2027 annual shareholder meeting or the one-year anniversary of the grant date, provided he continues serving as a director.
Disc Medicine, Inc. director Kevin Bitterman received a grant of stock options covering 6,212 shares of common stock. The options have an exercise price of $70.79 per share and expire on June 17, 2036.
The options vest on the earlier of the company’s 2027 annual stockholders’ meeting or the one-year anniversary of the grant date, subject to his continued service. Footnotes state that proceeds from any sale of shares issued upon exercise will be transferred to Atlas Venture Life Science Advisors, LLC, and Bitterman disclaims ownership of the securities except for any pecuniary interest.
Disc Medicine director Nadim Ahmed received a grant of stock options, giving him the right to buy 5,176 shares of common stock. The options have an exercise price of $70.79 per share and expire on June 17, 2036.
These options vest on the earlier of the company’s 2027 annual stockholders’ meeting or the one-year anniversary of the grant date, contingent on his continued board service. After this grant, Ahmed holds options covering 5,176 shares directly.
IRON notice of proposed sale: a Form 144 lists a proposed sale of 10,000 shares of Common Stock on 06/22/2026 tied to an exercise of stock options. The filing also discloses a 10b5-1 sale by Jonathan Yu of 18,612 shares on 06/16/2026 for $1,287,800.28.
Disc Medicine, Inc. Chief Operating Officer Yu Jonathan Yen-Wen reported option exercises and related share sales. On June 16, 2026, he exercised stock options for a total of 18,612 shares of common stock at an exercise price of $9.86 per share and sold 18,612 shares in open-market transactions. The sales occurred at weighted average prices of about $68.76 and $69.92 per share, within ranges from $68.37 to $70.19. The filing states these trades were executed under a pre-arranged Rule 10b5-1 trading plan, indicating they were scheduled in advance rather than timed discretionarily.
Disc Medicine reported a larger quarterly loss as it accelerates clinical development. For the three months ended March 31, 2026, net loss was $63.5 million (vs. $34.1 million), or $1.65 per share. Research and development rose to $45.9 million, driven by the DISC‑3405 program, milestones and higher headcount, while selling, general and administrative expenses increased to $23.6 million as the company builds commercial capabilities.
Disc ended the quarter with $730.2 million in cash, cash equivalents and marketable securities and expects this to fund operations and debt obligations into 2029. The pipeline includes Phase 3 bitopertin in erythropoietic porphyrias, DISC‑0974 in anemia of myelofibrosis and inflammatory bowel disease, and DISC‑3405 in polycythemia vera and sickle cell disease.